A
Aurion Biotech
Advanced Therapies for Ocular Diseases
About Aurion Biotech
Aurion Biotech is a clinical-stage biotech company that operates in the life sciences and biotechnology market. The company's primary mission is to restore vision to millions of patients through innovative regenerative therapies. They have recently been recognized as the "Regenerative Therapeutics Company of the Year" in the BioTech Breakthrough Awards program, highlighting their innovative approach and significant contributions to the field.
Aurion Biotech's primary offering is a patented cell therapy treatment for corneal endothelial disease, a condition that can lead to vision loss. The company recently reached a significant milestone by dosing the first subject in its Phase 1 / 2 U.S. clinical trial, marking a significant step forward in bringing their treatment to market.
The company's business model revolves around the development and commercialization of these advanced therapies for ocular diseases. They generate revenue by conducting clinical trials and eventually selling these treatments to patients in need. Their clients are primarily patients suffering from vision loss due to ocular diseases, specifically corneal endothelial dysfunction.
In summary, Aurion Biotech is a promising startup in the biotech industry, focusing on developing innovative regenerative therapies to restore vision to patients worldwide. Their commitment to research and development, coupled with their recent recognition in the BioTech Breakthrough Awards, positions them as a significant player in the life sciences and biotechnology market.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2021
- Headquarters
- Seattle, United States
- Employees
- 105
- Open positions
- 5
- Dealroom signal
- 86.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2025 | $0 | — | Alcon | ↗ |
| EARLY VCOther financing | Apr 2022 | $120M | $480M | Visionary Ventures · Flying L Partners · Petrichor · KKR | ↗ |
Growth signals
Latest recorded traffic for Aurion Biotech is 4.9K monthly website visits, down 10.9% over the last three months. Aurion Biotech's team grew 8.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
- VVVisionary Ventures
Flying L Partners- PEPetrichor
KKR
Falcon-vision
Deerfield
Alcon
Other known investors1 additional known investor
Kyoto Prefectural University of Medicine
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aurion Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aurion Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.